Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDBD for Adolescent and Young Adult Patients With Relapsed or Refractory T-ALL and Lymphomas
NCT07513129Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2026
- Primary completion
- Dec 2029
- Modality
- Monoclonal Antibodies, Modified Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of venetoclax, dexamethasone, bortezomib and daratumumab in t-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic lymphoma (T-LBL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Started Jun 2026; status: recruiting.
02
Drugs
venetoclaxdexamethasonebortezomibdaratumumab
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T cell lymphoblastic lymphoma (T-LBL)
Beyond the preview
Go deeper on NCT07513129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07513129.